U.S. Sales Growth Helps Teva Top Estimates in Q3

Teva Pharmaceutical (NYSE: TEVA  ) , one of the world's largest generic drug producers, reported its third-quarter results before the opening bell this morning just one day after its CEO, Jeremy Levin, announced he was stepping down from his role as CEO.

For the quarter, Teva delivered sales growth of 1.7% to $5.06 billion, helped primarily by generic and branded pharmaceutical growth in the United States, while producing a profit of $1.27 per share, down marginally from the $1.28 EPS reported in the year prior. Comparatively, Wall Street expected revenue of just $5 billion in sales and EPS of $1.26.

This quarter was really all about the U.S. in the positives column, and foreign-exchange rates in the negative.

Within the U.S., Teva grew its generic business by 6%, aided by the recent launch of generic versions of cholesterol drug Niaspan and brain tumor treatment Temodar. Its specialty brands segment (i.e., its branded drug segment) produced 3% growth, aided primarily by a price increase for Copaxone, the best selling multiple sclerosis drug in the world. Copaxone brought in $1.05 billion in worldwide revenue, up 1% from the prior year, and was responsible for nearly 21% of Teva's revenue this quarter.

On the flip side, Teva struggled in its rest of the world (ROW) market segment excluding Europe. Currency conversion, most notably from the Japanese Yen, produced a minus 8% effect on ROW revenue, which accounts for 18% of Teva's total sales. The company also pointed towards weaker sales of Copaxone in Russia when explaining the subpar results in this segment.

Sales in Europe were also affected negatively by fluctuating currencies, but to a lesser degree -- minus 4%. What weakness was visible in European generic operations, which saw sales decline by 1% (excluding currency effects), was more than made up for by 12% sales growth (excluding currency effects) in its specialty brands business.

Looking ahead, Teva tightened both its revenue and EPS projections from prior forecasts to a range of $19.7 billion to $20.3 billion in sales and $4.95-$5.05 in EPS.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2707897, ~/Articles/ArticleHandler.aspx, 9/28/2016 8:04:54 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:00 PM
TEVA $49.47 Down -0.80 -1.59%
Teva Pharmaceutica… CAPS Rating: ****